Wyniki wyszukiwania

1

Interaction of 2',2'-difluorodeoxycytidine [gemcitabine] with tumor necrosis factor alpha or its mutein VI in murine leukemias L1210 and P388

100%

Maranda E., Robak T.

Archivum Immunologiae et Therapiae Experimentalis

|

1998

|

tom 46

|

nr 2

2

DNA damage and apoptosis induction in L1210 cells by cis-diamminedichloroplatinum[II] and its new aminoflavone analogue

100%

Ciesielska E., Studzian K., Zyner E., Ochocki J., Szmigiero L.

Cellular and Molecular Biology Letters

|

2000

|

tom 05

|

nr 2

3

Drug-mediated ototoxicity and tinnitus: alleviation with melatonin

80%

Reiter R. J., Tan D.-X., Korkmaz A., Fuentes-Broto L.

Journal of Physiology and Pharmacology

|

2011

|

tom 62

|

nr 2

This review evaluates the published basic science and clinical reports related to the role of melatonin in reducing the side effects of aminoglycosides and the cancer chemotherapeutic agent cisplatin, in the cochlea and vestibule of the inner ear. A thorough search of the literature was performed using available databases for the purpose of uncovering articles applicable to the current review. Cochlear function was most frequently evaluated by measuring otoacoustic emissions and their distortion products after animals were treated with cytotoxic drugs alone or in combination with melatonin. Vestibular damage due to aminoglycosides was evaluated by estimating hair cell loss in explanted utricles of newborn rats. Tinnitus was assessed in patients who received melatonin using a visual analogue scale or the Tinnitus Handicap Inventory. Compared to a mixture of antioxidants which included tocopherol, ascorbate, glutathione and N-acetyl-cysteine, melatonin, also a documented antioxidant, was estimated to be up to 150 times more effective in limiting the cochlear side effects, evaluated using otoacoustic emission distortion products, of gentamicin, tobramycin and cisplatin. In a dose-response manner, melatonin also reduced vestibular hair cell loss due to gentamicin treatment in explanted utricles of newborn rats. Finally, melatonin (3 mg daily) limited subjective tinnitus in patients. These findings suggest the potential use of melatonin to combat the ototoxicity of aminoglycosides and cancer chemotherapeutic agents. Additional studies at both the experimental and clinical levels should be performed to further document the actions of melatonin at the cochlear and vestibular levels to further clarify the protective mechanisms of action of this ubiquitously-acting molecule. Melatonin’s low cost and minimal toxicity profile supports its use to protect the inner ear from drug-mediated damage.

4

Gemcitabine induced cell cycle disturbances and apoptosis in lung cancer cell lines; Basis for combination therapy with topotecan and taxol

80%

Kroep J. R., Giaccone G., Tolis C., Ferreira C. G., Pinedo H. M., Peters G. J.

Cellular and Molecular Biology Letters

|

1999

|

tom 04

|

nr 3

5

Genetic approaches for prevention of restenosis following percutaneous translumenal angioplasty

80%

Pirog E. C.

Bulletin of the Polish Academy of Sciences. Biological Sciences

|

1994

|

tom 42

|

nr 4

Ograniczanie wyników

2 Cellular and Molecular Biology Letters

1 Archivum Immunologiae et Therapiae Experimentalis

1 Bulletin of the Polish Academy of Sciences. Biological Sciences

1 Journal of Physiology and Pharmacology

1 Ciesielska E.

1 Ferreira C. G.

1 Fuentes-Broto L.

1 Giaccone G.

1 Korkmaz A.

1 Kroep J. R.

1 Maranda E.

1 Ochocki J.

1 Peters G. J.

1 Pinedo H. M.

1 Pirog E. C.

1 Reiter R. J.

1 Robak T.

1 Studzian K.

1 Szmigiero L.

1 Tan D.-X.

1 Tolis C.

1 Zyner E.

1 2011

1 2000

1 1999

1 1998

1 1994

Interaction of 2',2'-difluorodeoxycytidine [gemcitabine] with tumor necrosis factor alpha or its mutein VI in murine leukemias L1210 and P388

DNA damage and apoptosis induction in L1210 cells by cis-diamminedichloroplatinum[II] and its new aminoflavone analogue

Drug-mediated ototoxicity and tinnitus: alleviation with melatonin

Gemcitabine induced cell cycle disturbances and apoptosis in lung cancer cell lines; Basis for combination therapy with topotecan and taxol

Genetic approaches for prevention of restenosis following percutaneous translumenal angioplasty